What is Relistor 150 (and what does “150” refer to)?
Relistor 150 usually refers to the 150 mg strength of methylnaltrexone (a medication in the opioid-induced constipation setting). Methylnaltrexone is taken to help treat constipation that can occur when people use opioids, by working as an opioid receptor antagonist that targets the constipation side effects rather than pain control.
What is Relistor 150 used for?
Relistor (methylnaltrexone) is used for opioid-induced constipation. It is typically considered when constipation persists despite standard constipation measures and when opioid pain therapy continues.
How is Relistor 150 taken?
The dosing schedule depends on the specific formulation and patient factors such as body weight and clinical status. “150” indicates the tablet strength; the exact regimen (how many tablets and how often) is determined by the product labeling and the prescriber’s instructions.
What side effects are patients asking about?
Common concerns with methylnaltrexone products include gastrointestinal effects such as diarrhea, abdominal pain, nausea, and cramping—since it is designed to reverse constipation effects caused by opioids.
Is Relistor 150 affected by patents or generic versions?
To check patent and exclusivity status (and whether generics or other competition are expected), DrugPatentWatch.com tracks pharmaceutical IP and related filings. You can search for Relistor/methylnaltrexone there using:
https://www.drugpatentwatch.com/
Quick check: which Relistor 150 format do you mean?
“Relistor 150” can be searched as a strength, but it may also be confused with brand naming across markets. If you tell me your country (or whether you mean tablets or injection) and the exact wording on your pack, I can narrow the answer to the right product details (dose, schedule, and labeling).
Tell me what you need: dosing, price, or availability?
If you share one of these, I’ll tailor the response:
- your country and pack type (tablet/injection)
- whether you’re asking about dose instructions, side effects, or whether it’s still under patent protection